Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,108
archived clinical trials in
Lupus

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Columbia Presbyterian Med Ctr
mi
from
New York, NY
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of Toledo Medical Center
mi
from
Toledo, OH
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of Toledo Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania Health Systems
mi
from
Philadelphia, PA
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania Health Systems
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Low Country Rheumatology
mi
from
Charleston, SC
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Low Country Rheumatology
mi
from
Charleston, SC
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Austin Regional Clinic
mi
from
Austin, TX
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Austin Regional Clinic
mi
from
Austin, TX
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
The Seattle Arthritis Clinic
mi
from
Seattle, WA
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
The Seattle Arthritis Clinic
mi
from
Seattle, WA
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Dermatology Institute and Skin Care Center
mi
from
Santa Monica, CA
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Dermatology Institute and Skin Care Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Los Angeles Biomedical Research Institute at Harbor-UCLA
mi
from
Torrance, CA
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Los Angeles Biomedical Research Institute at Harbor-UCLA
mi
from
Torrance, CA
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
NYU Langone Medical Center
mi
from
New York, NY
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
DJL Clinical Research
mi
from
Charlotte, NC
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
DJL Clinical Research
mi
from
Charlotte, NC
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Emory University School of Medicine
mi
from
Atlanta, GA
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Feinstein Institute, North Shore Hospital
mi
from
Manhasset, NY
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Feinstein Institute, North Shore Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
New York University Langone Medical Center
mi
from
New York, NY
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Medical College: Hospital for Special Surgery -
mi
from
New York, NY
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medical College: Hospital for Special Surgery -
mi
from
New York, NY
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of North Carolina School of Medicine
mi
from
Chapel Hill, NC
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of North Carolina School of Medicine
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern
mi
from
Dallas, TX
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
UCLA Medical Center: Division of Rheumatology
mi
from
Los Angeles, CA
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
UCLA Medical Center: Division of Rheumatology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver: School of Medicine: Division of Rheumatology
mi
from
Aurora, CO
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver: School of Medicine: Division of Rheumatology
mi
from
Aurora, CO
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Colorado Kidney Care
mi
from
Denver, CO
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Colorado Kidney Care
mi
from
Denver, CO
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Rituximab and Belimumab for Lupus Nephritis
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
mi
from
Long Beach, CA
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Harbor UCLA Medical Center
mi
from
Torrance, CA
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Harbor UCLA Medical Center
mi
from
Torrance, CA
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center
mi
from
Farmington, CT
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center
mi
from
Farmington, CT
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Center for Rheumatology, Immunology and Arthritis
mi
from
Fort Lauderdale, FL
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Center for Rheumatology, Immunology and Arthritis
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
The Arthritis Center
mi
from
Palm Harbor, FL
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
The Arthritis Center
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Med. Center Div. Of Gastroenterology
mi
from
Boston, MA
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Med. Center Div. Of Gastroenterology
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Physician Research Collaboration
mi
from
Lincoln, NE
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Physician Research Collaboration
mi
from
Lincoln, NE
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
North Shore-LIJ Health System
mi
from
Great Neck, NY
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
North Shore-LIJ Health System
mi
from
Great Neck, NY
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Joint And Muscle Medical Care And Research Institute (Jmmcri)
mi
from
Charlotte, NC
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Joint And Muscle Medical Care And Research Institute (Jmmcri)
mi
from
Charlotte, NC
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Pmg Research Of Salisbury
mi
from
Salisbury, NC
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Pmg Research Of Salisbury
mi
from
Salisbury, NC
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
East Penn Rheumatology Associates, P.C.
mi
from
Bethlehem, PA
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
East Penn Rheumatology Associates, P.C.
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Allegheny-Singer Research Institute (Asri)
mi
from
Pittsburgh, PA
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Allegheny-Singer Research Institute (Asri)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Tekton Research
mi
from
Austin, TX
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Tekton Research
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Arthritis Northwest
mi
from
Spokane, WA
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Arthritis Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials